Swedish Orphan Biovitrum AB (SOBI) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Swedish Orphan Biovitrum Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.377 Hello, everyone. This is Guido Erckes, CEO of Sobi. 00:00:04.377 -- 00:00:10.106 We are delighted to welcome you to the fourth quarter and full year 2025 00:00:10.106 -- 00:00:13.090 conference call for investors and analysts. 00:00:13.090 -- 00:00:18.177 We posted this presentation to sobi.com earlier today. 00:00:18.177 -- 00:00:23.565 We would like to remind you of usual provisions on statements about expectations 00:00:23.565 -- 00:00:29.613 and projections of future events. Unless otherwise stated, 00:00:29.613 -- 00:00:34.179 we will make comments mostly relate to the second 00:00:34.179 -- 00:00:39.445 quarter at constant currency, or fourth quarter, apologies, 00:00:39.445 -- 00:00:44.912 and a million Swedish krona. Today we plan to cover the key aspects of our Q4 00:00:44.912 -- 00:00:50.499 report. I'm joined by Henrik Stenqvist, our CFO, and Lydia 00:00:50.499 -- 00:00:53.843 Abarth-Franz, head of R&D and chief medical officer. 00:00:53.843 -- 00:00:59.260 We plan to review the presentation first and then have a question an answer session 00:00:59.260 -- 00:01:04.309 until around 2 p.m. For those on the phone, please join the queue for 00:01:04.309 -- 00:01:09.838 questions by pressing star one. We propose you ask only one question 00:01:09.838 -- 00:01:15.147 or two max at a time. So with this, let's go straight to the key takeaways 00:01:15.147 -- 00:01:18.412 for the fourth quarter. 00:01:18.412 -- 00:01:24.828 It has been a quarter for Suvi along various dimensions, you know, financially, strategically, 00:01:24.828 -- 00:01:29.973 and scientifically, and I'm pleased to say that we demonstrated significant progress 00:01:29.973 -- 00:01:35.416 along all these three areas in 2025. In 00:01:35.578 -- 00:01:40.022 the ...